Unit:
Κατεύθυνση Μοριακή Ιατρική ΒιοπαθολογίαLibrary of the School of Health Sciences
Author:
Amargianitaki Eirini
Supervisors info:
Ιωσήφ Παπαπαρασκευάς, Αναπληρωτής Καθηγητής, Ιατρική Σχολή, ΕΚΠΑ
Αθανάσιος Τσακρής, Καθηγητής, Ιατρική Σχολή, ΕΚΠΑ
Βασιλική Κουμάκη, Επίκουρη Καθηγήτρια, Ιατρική Σχολή, ΕΚΠΑ
Original Title:
Η εφαρμογή του νέου αναστολέα vaborbactam στη θεραπευτική των λοιμώξεων
Translated title:
The use of vaborbactam, a new b-lactamase inhibitor, in the treatment of infections
Summary:
Infections due to carbapenem-resistant Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter baumannii constitute a global health threat and are associated with significant morbidity and mortality. Resistance is mainly due to the production of carbapenemases.
Vaborbactam is a novel β-lactamase inhibitor. It is a cyclic boronic acid-based inhibitor with high potency against class A carbapenemases, including KPC. Combined with meropenem, it almost fully restores its activity against carbapenemase-producing Enterobacterales. However, it has limited activity against Pseudomonas aeruginosa and Acinetobacter baumannii. Clinical efficacy and safety of the combination were evaluated in two clinical trials, TANGO I and II, where meropenem/vaborbactam was found to be non-inferior compared to other therapeutic options. It was also found to be safe, having few serious adverse effects, especially in terms of nephrotoxicity. Based on available in vitro and in vivo data it appears to retain a low propensity for resistance selection. It exhibits pharmacokinetic properties that are similar to those of meropenem. Meropenem/vaborbactam has been approved for use in adults with complicated urinary tract infections, complicated intrabdominal infections, hospital-acquired pneumonia and ventilator-associated pneumonia, and infections due to aerobic Gram-negative organisms in adults with limited treatment options. Studies regarding its use in real-life settings show promising clinical cure rates and lower rates of adverse effects, even when it comes to cases of very fragile patients.
Main subject category:
Health Sciences
Keywords:
Carbapenem-resistant organisms, Klebsiella pneumoniae carbapenemase, Vaborbactam, Meropenem/vaborbactam
Number of references:
145
